Charles River Laboratories Intl. Inc vs Peloton Interactive Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $285.47 (market cap $13.46B), while Peloton Interactive Inc trades at $5.43 (market cap $2.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.5× Peloton Interactive Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals.
| CRL | PTON | |
|---|---|---|
Market Cap | $13.46B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $282.00 | $9.00 |
52-Week Low | $145.57 | $3.71 |
Enterprise Value | $16.30B | $2.96B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Peloton Interactive (PTON) trades at $5.42, down 1.63% today, with a bearish technical signal and negative shareholder equity. The company achieved its first annual net profit in fiscal 2026, with Q4 earnings beating estimates at $0.13 per share. Revenue declined to $2.49 billion in 2025, but net losses narrowed significantly to $119 million. Cash flow turned positive at $335 million, and debt-to-asset ratio improved to 63.18% in 2026. Analyst sentiment is mixed with a 50% buy rating.
Outlook remains cautious due to ongoing revenue declines and high debt, but profitability improvements and cost controls provide a foundation for recovery. Key risks include subscriber losses, competitive pressures, and patent litigation. The stock offers speculative upside if growth stabilizes, but requires careful risk management.
Trailing returns across standard periods
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →